Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry

Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review.

OBJECTIVE To evaluate the safety, efficacy, and effectiveness of TNF antagonists in patients with sarcoidosis. METHODS A descriptive study of a case series registered in BIOBADASER and a systematic review was performed. The search strategy of articles published between 1998 and July 2011 in Medline, Embase, and the Cochrane Library included synonyms of sarcoidosis and synonyms of TNF antagoni...

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

The aim of the present work is to compare drug survival and safety of infliximab, etanercept, and adalimumab (tumor necrosis factor [TNF] antagonists) in spondylarthritis (SpA) with those of rheumatoid arthritis (RA). To this purpose, we analysed the data in BIOBADASER (2000-2005), a drug registry launched in 2000 for long-term follow-up of the safety of these biologics in rheumatic diseases. T...

Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.

OBJECTIVE To compare the safety and retention rate of TNF antagonists used in approved indications (AIs) and non-AIs. METHODS Analysis of the Spanish registry BIOBADASER 2.0 (February 2000 to October 2009). Patients were classified into AIs and off-label uses (OUs), according to the European Medicines Agency approval. Retention rates, incidence rates (IRs) and IR ratios (IRRs) of adverse even...

PM381. Reason for clozapine discontinuation

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry

OBJECTIVES To study the number of patients that taper or discontinue concomitant methotrexate (MTX) in daily practice in patients with rheumatoid arthritis (RA) treated with tumour necrosis factor inhibitor (TNFi) and to analyse the effects of that adaption on disease activity and drug survival. METHODS Data were collected from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Patie...